1
|
Mohan KN. Editorial: New insights into investigating schizophrenia as a disorder of molecular pathways. Front Mol Neurosci 2024; 17:1360616. [PMID: 38274843 PMCID: PMC10805877 DOI: 10.3389/fnmol.2024.1360616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Accepted: 01/02/2024] [Indexed: 01/27/2024] Open
Affiliation(s)
- Kommu Naga Mohan
- Molecular Biology and Genetics Laboratory, Department of Biological Sciences, BITS Pilani Hyderabad Campus, Hyderabad, India
- Centre for Human Disease Research, BITS Pilani Hyderabad Campus, Hyderabad, India
| |
Collapse
|
2
|
Ping J, Wan J, Huang C, Yu J, Luo J, Xing Z, Luo X, Du B, Jiang T, Zhang J. DNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia. Ann Gen Psychiatry 2023; 22:40. [PMID: 37833704 PMCID: PMC10576382 DOI: 10.1186/s12991-023-00466-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 09/18/2023] [Indexed: 10/15/2023] Open
Abstract
OBJECTIVE Schizophrenia is a serious mental disorder with complex clinical manifestations, while its pathophysiological mechanism is not fully understood. Accumulated evidence suggested the alteration in epigenetic pathway was associated with clinical features and brain dysfunctions in schizophrenia. DNA methyltransferases (DNMTs), a key enzyme for DNA methylation, are related to the development of schizophrenia, whereas the current research evidence is not sufficient. The aim of study was to explore the effects of gene polymorphisms of DNMTs on the susceptibility and symptoms of schizophrenia. METHODS The study was case-control study that designed and employed the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) as the diagnostic standard. 134 hospitalized patients with schizophrenia in the Third People's Hospital of Zhongshan City from January 2018 to April 2020 (Case group) as well as 64 healthy controls (Control group) from the same region were involved. Single nucleotide polymorphisms (SNPs) of DNMT1 genes (r s2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) were determined with massARRAY. Linkage disequilibrium analysis and haplotype analysis were performed, and genotype and allele frequencies were compared. The Hardy-Weinberg equilibrium was tested by the Chi-square test in SPSS software (version 20.0, SPSS Inc., USA). The severity of clinical symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). The correlation between DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs2424932, rs1569686, rs6119954 and rs2424908) and clinical features was analyzed. RESULTS There were no significant differences in genotype, allele frequency and haplotype of DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) between the case and healthy control group. There were significant differences in the PANSS total positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) in patients with different DNMT1 gene rs 2114724 and rs 2228611 genotypes. The linkage disequilibrium analysis of gene polymorphic loci revealed that rs 2114724-rs 2228611 was complete linkage disequilibrium, and rs 1569686-rs 2424908, rs 2424932-rs 1569696 and rs 2424932-rs 2424908 were strongly linkage disequilibrium. CONCLUSION The polymorphisms alteration in genetic pathway may be associated with development of specific clinical features in schizophrenia.
Collapse
Affiliation(s)
- Junjiao Ping
- Department of Psychiatry, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
- Joint Laboratory of Psychiatric Genetic Research, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Jing Wan
- Department of Early Intervention, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Caiying Huang
- Department of Early Intervention, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Jinming Yu
- Department of Psychiatry, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Jiali Luo
- Joint Laboratory of Psychiatric Genetic Research, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Zhiqiang Xing
- Department of Psychiatry, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Xingguang Luo
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 06510, USA
| | - Baoguo Du
- Department of Clinical Psychology, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China
| | - Tingyun Jiang
- Department of Psychiatry, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China.
| | - Jie Zhang
- Joint Laboratory of Psychiatric Genetic Research, The Third People's Hospital, Zhongshan, 528451, Guangdong, People's Republic of China.
- Department of Psychiatry, Gannan Medical University, Ganzhou, 341000, Jiangxi , People's Republic of China.
| |
Collapse
|